CN114366712A - 用于治疗脉络膜新生血管的药物凝胶混合物 - Google Patents
用于治疗脉络膜新生血管的药物凝胶混合物 Download PDFInfo
- Publication number
- CN114366712A CN114366712A CN202210111019.8A CN202210111019A CN114366712A CN 114366712 A CN114366712 A CN 114366712A CN 202210111019 A CN202210111019 A CN 202210111019A CN 114366712 A CN114366712 A CN 114366712A
- Authority
- CN
- China
- Prior art keywords
- drug
- gel mixture
- choroidal neovascularization
- pharmaceutical
- tgms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000005590 Choroidal Neovascularization Diseases 0.000 title claims abstract description 39
- 206010060823 Choroidal neovascularisation Diseases 0.000 title claims abstract description 39
- 239000008252 pharmaceutical gel Substances 0.000 title claims description 16
- 239000003814 drug Substances 0.000 claims abstract description 47
- 229940079593 drug Drugs 0.000 claims abstract description 43
- 239000000017 hydrogel Substances 0.000 claims abstract description 42
- 239000000499 gel Substances 0.000 claims abstract description 40
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims description 32
- 229960003895 verteporfin Drugs 0.000 claims description 29
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 claims description 10
- 102000004882 Lipase Human genes 0.000 claims description 10
- 108090001060 Lipase Proteins 0.000 claims description 10
- 239000004367 Lipase Substances 0.000 claims description 10
- 235000019421 lipase Nutrition 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 abstract description 6
- 238000011065 in-situ storage Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000000520 microinjection Methods 0.000 abstract description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 13
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 13
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 10
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 208000019553 vascular disease Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 7
- 238000002428 photodynamic therapy Methods 0.000 description 7
- 108700038175 YAP-Signaling Proteins Proteins 0.000 description 6
- 238000013534 fluorescein angiography Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940023490 ophthalmic product Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 230000004655 Hippo pathway Effects 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007360 epithelial dysfunction Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Abstract
本发明提供了一种用于治疗脉络膜新生血管的药物凝胶混合物,所述药物凝胶混合物包括可注射水凝胶以及用于治疗脉络膜新生血管的药物。本发明所提供的用于治疗脉络膜新生血管的药物凝胶混合物能实现眼内原位微量注射给药,从而抑制新生血管形成。
Description
技术领域
本发明涉及一种药物,特别涉及用于治疗脉络膜新生血管的药物,尤其涉及用于治疗脉络膜新生血管的药物凝胶混合物。
背景技术
眼睛中的眼底脉络膜是一个高度血管化的网络,滋养光感受器和视网膜色素上皮细胞,清除视网膜的代谢废物。脉络膜疾病主要表现为进行性视网膜色素上皮的功能障碍,以及引起脉络膜血管疾病的脉络膜血管构筑和功能异常,如与年龄相关性黄斑变性相关的脉络膜新生血管(CNV),息肉状脉络膜血管病变(PCV)和中心性浆液性脉络膜视网膜病变等。许多流行病学研究表明,脉络膜血管疾病影响范围广泛,并且在随后的十年中,世界范围内的发病率呈指数级增长。脉络膜血管疾病的病理过程可归因于渗出性变化,包括血管通透性增加和新生血管形成,导致视觉功能严重受损,甚至不可逆失明。尽管脉络膜血管疾病通常是多因素的,其分子发病机制尚待阐明,但毛细血管的异常发育与血管内皮生长因子(VEGF)和广泛的细胞外基质相关蛋白,如基质金属蛋白酶(MMPs),在炎性微环境中的产生增加有关。
临床上,治疗脉络膜新生血管疾病的治疗策略之一是光动力疗法(PDT),它使用689nm激光激活静脉注入的光敏剂维替泊芬(VP),在氧化应激条件下产生活性氧并诱导血管内皮细胞凋亡,以减少渗漏和闭塞血管。VP-PDT已广泛应用于治疗CNV、PCV和其他脉络膜血管疾病,具有很好的治疗效果。然而,为了使药物在循环至脉络膜血管网时达到足够的血清浓度,临床实践中需要6mg/m2的高注射剂量VP(约15mg)。此外,静脉注射会增加全身系统不良反应的风险,如光敏反应、胸痛和呼吸急促等。此外,为了避免光敏剂对其他组织,尤其是皮肤组织造成损害,患者在注射药物后至少需要48小时内避免光照,这使得光照保护对患者不方便,并导致患者依从性差。此外,尽管VP-PDT导致病理性新生血管的血管阻塞,但视网膜下间隙多余的VEGF水平仍然是复发的驱动力,这需要额外的抗VEGF药物联合治疗。因此,制定一项解决这些问题的新策略可能有利于脉络膜血管疾病患者。
除了光化学特性外,VP还是yes相关蛋白(YAP)的有效抑制剂,yes相关蛋白是Hippo-YAP信号的关键调节因子,该信号通路已被证明是组织维持和器官大小调节的关键信号通路。VP可以抑制Hippo途径中的YAP转录活性,从而调节组织发育。新的研究揭示了VEGF和Hippo-YAP信号之间的潜在偶联,这一点尚未在临床应用中得到应用。YAP信号可能作为一个枢纽来介导下游促血管生成表型。然而,VP的光动力学和非光动力学功能的结合是否在阻止病理性新生血管形成中起作用仍有待阐明。
发明内容
有鉴于现有技术的上述缺陷,本发明提供了一种用于治疗脉络膜新生血管的药物凝胶混合物,要解决的技术问题是实现眼内原位微量注射给药,从而抑制新生血管形成。
为解决上述问题,本发明采取的技术方案是:一种用于治疗脉络膜新生血管的药物凝胶混合物,所述药物凝胶混合物包括可注射水凝胶以及用于治疗脉络膜新生血管的药物。
优选地,所述药物凝胶混合物的制备方法包括:
1)提供所述的可注射水凝胶以及所述的用于治疗脉络膜新生血管的药物;
2)加热使所述的可注射水凝胶溶解;
3)将所述的用于治疗脉络膜新生血管的药物添加到溶解后的可注射水凝胶,混合;
4)冷却成凝胶状,以形成所述的药物凝胶混合物。
优选地,所述的用于治疗脉络膜新生血管的药物为维替泊芬。
优选地,所述可注射水凝胶为三聚甘油单硬脂酸酯。
优选地,所述的药物凝胶混合物为孔状结构。
优选地,所述的药物凝胶混合物被配置为能用30G注射器注射。
优选地,所述的药物凝胶混合物被配置为:在应力作用下,凝胶网络被破坏并转变为液态。
优选地,所述的药物凝胶混合物被配置为:当应力撤销后,液态恢复为凝胶态。
优选地,所述的药物凝胶混合物被配置为:在脂肪酶存在的环境中,所述的药物凝胶混合物持续地释放所述的用于治疗脉络膜新生血管的药物,且释放量多于无脂肪酶存在的环境。
本发明的有益效果为:本发明主要着眼于眼科药物递送生物材料领域,由于眼部生物屏障的影响、药物的快速清除及缺乏控释和生物粘附性,传统眼科药物的治疗效果较低,生物利用度低,利用眼部组织独特的物理化学特征,让药物配方组合不同的原位水凝胶聚合物,且具有不同的刺激响应机制,这是一种与传统给药系统相比产生改进效果的策略。水凝胶载药系统使用可生物降解和生物相容性聚合物,已被证明是有效的给药策略,可使得眼科药物的生物利用度大大增加。用于眼后段给药的原位凝胶载药系统能够提高眼科药物制剂的生物利用度。本发明提供了一种使用美国食品和药物管理局批准的两亲性制剂三聚甘油单硬脂酸酯(TGMS)来封装VP的原位药物递送系统。原位凝胶药物递送系统对脉络膜血管疾病患者玻璃体腔内MMP-2和MMP-9表达增加的刺激有响应。值得注意的是,药物输送系统设计用于提供以下好处:1)在光动力条件下,该系统可以利用低剂量的VP来实现类似的治疗效果,同时避免全身光敏反应,从而实现光激活VP的对症疗效。2)在非光动力条件下,本发明系统可以实现非光激活VP作为YAP抑制剂对VEGFR2信号的影响,从而实现对因治疗。重要的是,本发明系统最大程度地受益于VP在光照和非光照条件下的理化和生物功能,从而大大增强抗血管生成治疗的协同效应,这可能为脉络膜血管疾病的治疗提供新的见解。
以下将结合附图对本发明的构思、具体结构及产生的技术效果作进一步说明,以充分地了解本发明的目的、特征和效果。
附图说明
图1显示实施例1中制备的VP-TGMS水凝胶的扫描电镜照片。
图2显示实施例1中制备的VP-TGMS水凝胶的应变相关振荡测量结果。
图3显示实施例1中制备的VP-TGMS水凝胶的阶跃应变测量。
图4显示实施例2中通过ELISA测定脉络膜血管疾病患者眼玻璃体中MMP-2和MMP-9的平均浓度(n=4)。
图5显示实施例2中VP-TGMS水凝胶在体外针对脂肪酶释放VP的能力。其中,在37℃条件下,脂肪酶为蓝绿假单胞菌脂肪酶(500U/mL或1000U/mL),VP-TGMS水凝胶与脂肪酶在指定时间点(箭头所示)(n=3)孵育。
图6显示实施例2中VP-TGMS水凝胶在体外针对基质金属蛋白酶释放VP的能力。其中,MMP-2为100ng/mL,MMP-9为15ng/mL,VP-TGMS水凝胶与MMP-2、MMP-9和MMP-2/9抑制剂在指定时间点(箭头所示)(n=3)孵育。
图7显示实施例3中利用VP-TGMS水凝胶对CNV小鼠进行治疗(光动力治疗条件下)的荧光素血管造影图像,其中,代表性的红外(IR)眼底图像和FA图像显示注射前后脉络膜新生血管渗漏情况。
图8显示图7所示的图像的新生血管渗漏区荧光像素强度的定量结果。
图9显示实施例3中RPE/脉络膜铺片的IB4(新生血管的生物标记物)染色图像,其中,不同处理的眼睛中IB4染色显示CNV区域。
图10显示图9所示的图像的CNV区域的定量结果。
图11显示实施例4中利用VP-TGMS水凝胶对CNV小鼠进行治疗(非光动力条件下)的荧光素血管造影图像,其中,代表性的红外(IR)眼底图像和FA图像显示注射前后脉络膜新生血管渗漏情况。
图12显示图11所示的图像的新生血管渗漏区荧光像素强度的定量结果。
图13显示实施例4中RPE/脉络膜铺片的IB4(新生血管的生物标记物)染色图像,其中,不同处理的眼睛中IB4染色显示CNV区域。
图14显示图13所示的图像的CNV区域的定量结果。
具体实施方式
实施例1药物凝胶混合物的制备
在该实施例中,选用美国食品和药物管理局批准的两亲性制剂三聚甘油单硬脂酸酯(TGMS)作为凝胶,选用维替泊芬(VP)作为治疗脉络膜新生血管的药物。
称取1g VP,并将其添加到带有磁力搅拌转子的小瓶中,加入10mL二甲基亚砜-水混合物(8mL无菌水和2mL二甲基亚砜)。将小瓶悬浮在装满水的烧杯中,并使用磁力搅拌器加热至60–80℃。TGMS溶解且溶液变得均匀后,再向小瓶中添加3mg的VP(终浓度为0.3mg/mL)。冷却至室温约30分钟后,VP-TGMS变成凝胶状。
制备的VP-TGMS水凝胶在扫描电镜下呈现为多孔状结构(如图1所示)。
经过试验证明,制备的VP-TGMS水凝胶可以通过30G注射器进行注射。
为了探索VP-TGMS水凝胶的力学性能,使用应力控制流变仪进行了应变相关振荡测量。观察到凝胶网络被破坏并转变为液态的临界应变值为1.5%,进一步表明水凝胶具有优异的剪切变稀特性(如图2所示)。阶跃应变测量用于检查水凝胶机械性能的恢复能力。当凝胶经受高强度应变(100%)时,G’(弹性模量)从~1600Pa急剧下降至~5Pa,这小于G”(损耗模量)。当停止高应变并在此阶段施加低幅度应变(γ=0.1%)时,水凝胶的机械性能在几秒钟内完全恢复(如图3所示)。因此,VP-TGMS凝胶的力学性能可在多次破碎和重整循环后恢复,进一步表明制备的VP-TGMS水凝胶具有良好的可逆性和可注射性。
水凝胶的渗透压和pH值:为了进一步探讨VP-TGMS是否适合作为眼内给药载体,测定了VP-TGMS的pH值和渗透压。VP-TGMS胶束溶液的pH值测量值约为7.88±0.02,在人眼的耐受pH范围(4-8)内。VP-TGMS水凝胶的渗透压测试结果为281±3.7mOsm/kg,接近人玻璃体体液的渗透压(289.5±6.9mOsm/kg)。
实施例2药物凝胶混合物的酶响应特性
在本实施例中,申请人研究了脉络膜血管疾病患者眼玻璃体中MMP-2和MMP-9的表达水平,ELISA结果表明,与对照组相比,PCV患者的玻璃体体液样本中MMP-2和MMP-9水平显著上调(如图4所示)。表明眼内病理性血管生成可诱导MMP-2/9的刺激水平上调。接下来,申请人评估了实施例1中制备的VP-TGMS水凝胶在体外分解和释放VP的酶响应能力。VP-TGMS凝胶在含有或不含有脂肪酶(500U/mL或1000U/mL)、MMP-2(100ng/mL)或MMP-9(15ng/mL)的PBS中培养。MMP-2和MMP-9的浓度是根据玻璃体样本中检测到的值来选择的。如图5所示,重复的脂肪酶添加导致VP的累积释放显著增加,而PBS中的VP-TGMS呈现稳定状态,没有明显的水解。在确定的时间点多次添加MMP-2(100ng/mL)或MMP-9(15ng/mL),进一步观察VP的按需释放(如图6所示)。与PBS对照组相比,第28天的累积VP释放量分别增加了32.02±2.29%和14.62±1.40%。通过预先添加MMP-2/9抑制剂,在含有MMP-2或MMP-9的溶液中包裹的VP的释放被显著抑制。因此,VP负载MMP响应性水凝胶能够实现刺激响应性释放。
实施例3药物凝胶混合物在光动力治疗条件下封闭脉络膜新生血管的效果
为了研究玻璃体内注射实施1中制备的VP-TGMS水凝胶的光动力治疗效果,申请人建立了激光诱导的脉络膜新生血管小鼠模型。新生血管具有可变的毛细血管结构和形态,其特征是高渗透性,导致新生血管渗漏。
VP-TGMS水凝胶玻璃体腔内注射给药及治疗方法:对于玻璃体内注射,首先麻醉小鼠,扩散瞳孔,并用盐酸奥昔布卡因滴眼液局部麻醉眼表。然后在体视显微镜下用直径为0.3mm的针头在角膜缘后方1mm处切开。拔出针头后,沿切口插入微量注射器的针头,然后缓慢注射2μL的VP-TGMS(0.3mg/mL)。在PDT治疗组中,通过裂隙灯适配器(Quantel Medical,USA)在靶区选择689nm波长和300μm光斑大小的激光诱导VP选择性激活。600mW/cm2的激光辐照度持续83秒(临床使用的时间长度),以获得50J/cm2的光能。在非PDT治疗组,将小鼠置于15-20lx的标准照明下。
在激光光凝后第7天,在给药前进行荧光素血管造影(FA)以记录血管渗漏。在第8天,对小鼠进行不同的治疗,并在治疗7天后再次获得FA图像,以评估VP-TGMS水凝胶对脉络膜新生血管通透性的光动力效应。与注射前一致,生理盐水处理和空白TGMS处理的小鼠在注射后显示出明显的血管渗漏(如图7所示)。值得注意的是,在光动力条件下,经VP-TGMS处理和VP-I.V.处理的小鼠显示血管渗漏明显减弱,表明光激活了VP并有效地堵塞了渗漏血管(如图7和图8所示)。随后,VP-TGMS水凝胶的光动力效应通过RPE/脉络膜铺片的IB4(新生血管的生物标记物)染色进行评估。通过测量荧光强度来评估新生成的CNV的大小。如附图9所示,经VP-TGMS治疗的眼睛CNV病变面积显著减少69.34%,与静脉注射VP后观察到的治疗效果相当(69.86%)(如图9和图10所示),进一步表明光激活VP-TGMS在抑制新生血管病变方面的有效性和特异性。
实施例4药物凝胶混合物在非光动力条件下抑制新生血管生成的效果
申请人进一步研究了实施例1中制备的VP-TGMS水凝胶载药体系在非光激发的情况下对CNV小鼠模型中的作用。先进行激光光凝以产生CNV模型。随后,用(A)生理盐水,(B)空白TGMS水凝胶,(C)VP-TGMS水凝胶或(D)VP-I.V.(静脉注射)处理小鼠。然后,在没有激光激活的情况下,将小鼠置于标准照明(15–20lx)下。给药7天后进行FA。与生理盐水对照组相比,VP-TGMS治疗显著减少荧光素渗漏,而空白TGMS凝胶或静脉注射VP的小鼠没有显著抑制渗漏(如图11和图12所示)。申请人通过用IB4铺片染色检测新生血管形成进一步证实了这些发现,这表明VP-TGMS水凝胶可以有效地减小CNV病变的大小(如图13和14所示)。相比之下,静脉注射非光活性VP不会抑制CNV的形成(如图13和14所示),进一步证明从VP-TGMS水凝胶中持续释放非光活性VP可以显著抑制新生血管。由于游离VP在体循环中的半衰期较短(2-3h),在能够稳定发挥其YAP抑制作用之前,可能已从体内清除。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术人员无需创造性劳动就可以根据本发明的构思作出诸多修改和变化。因此,凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到的技术方案,皆应在由权利要求书所确定的保护范围内。
Claims (10)
1.一种用于治疗脉络膜新生血管的药物凝胶混合物,其特征在于,所述药物凝胶混合物包括可注射水凝胶以及用于治疗脉络膜新生血管的药物。
2.如权利要求1所述的药物凝胶混合物,其特征在于,所述药物凝胶混合物的制备方法包括:
1)提供所述的可注射水凝胶以及所述的用于治疗脉络膜新生血管的药物;
2)加热使所述的可注射水凝胶溶解;
3)将所述的用于治疗脉络膜新生血管的药物添加到溶解后的可注射水凝胶,混合;
4)冷却成凝胶状,以形成所述的药物凝胶混合物。
3.如权利要求1所述的药物凝胶混合物,其特征在于,所述的用于治疗脉络膜新生血管的药物为维替泊芬。
4.如权利要求1所述的药物凝胶混合物,其特征在于,所述可注射水凝胶为三聚甘油单硬脂酸酯。
5.如权利要求1所述的药物凝胶混合物,其特征在于,所述的药物凝胶混合物为孔状结构。
6.如权利要求1所述的药物凝胶混合物,其特征在于,所述的药物凝胶混合物被配置为能用30G注射器注射。
7.如权利要求1所述的药物凝胶混合物,其特征在于,所述的药物凝胶混合物被配置为:在应力作用下,凝胶网络被破坏并转变为液态。
8.如权利要求7所述的药物凝胶混合物,其特征在于,所述的药物凝胶混合物被配置为:当应力撤销后,液态恢复为凝胶态。
9.如权利要求1所述的药物凝胶混合物,其特征在于,所述的药物凝胶混合物被配置为:在脂肪酶存在的环境中,所述的药物凝胶混合物持续地释放所述的用于治疗脉络膜新生血管的药物,且释放量多于无脂肪酶存在的环境。
10.如权利要求1所述的药物凝胶混合物,其特征在于,所述的药物凝胶混合物被配置为:在基质金属蛋白酶存在的环境中,所述的药物凝胶混合物持续地释放所述的用于治疗脉络膜新生血管的药物,且释放量多于无基质金属蛋白酶存在的环境。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210111019.8A CN114366712B (zh) | 2022-01-25 | 2022-01-25 | 用于治疗脉络膜新生血管的药物凝胶混合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210111019.8A CN114366712B (zh) | 2022-01-25 | 2022-01-25 | 用于治疗脉络膜新生血管的药物凝胶混合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114366712A true CN114366712A (zh) | 2022-04-19 |
CN114366712B CN114366712B (zh) | 2023-10-24 |
Family
ID=81145055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210111019.8A Active CN114366712B (zh) | 2022-01-25 | 2022-01-25 | 用于治疗脉络膜新生血管的药物凝胶混合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114366712B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115671036A (zh) * | 2022-11-15 | 2023-02-03 | 上海交通大学医学院附属第九人民医院 | 用于治疗眼底和眼内疾病的凝胶药物 |
CN115678048A (zh) * | 2022-11-27 | 2023-02-03 | 福州大学 | 一种可促进创面愈合并减少疤痕形成的可注射复合水凝胶及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101426473A (zh) * | 2006-02-22 | 2009-05-06 | I科学干预公司 | 用于脉络膜上的药物递送的仪器和制剂 |
CN102380098A (zh) * | 2003-08-27 | 2012-03-21 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
US20170087248A1 (en) * | 2015-09-25 | 2017-03-30 | Jennifer J. KANG-MIELER | Biodegradable microsphere-hydrogel ocular drug delivery system |
CN113939271A (zh) * | 2019-04-25 | 2022-01-14 | 视觉治疗股份有限公司 | 眼用水凝胶酪氨酸激酶抑制剂植入物 |
-
2022
- 2022-01-25 CN CN202210111019.8A patent/CN114366712B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102380098A (zh) * | 2003-08-27 | 2012-03-21 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
CN101426473A (zh) * | 2006-02-22 | 2009-05-06 | I科学干预公司 | 用于脉络膜上的药物递送的仪器和制剂 |
US20170087248A1 (en) * | 2015-09-25 | 2017-03-30 | Jennifer J. KANG-MIELER | Biodegradable microsphere-hydrogel ocular drug delivery system |
CN113939271A (zh) * | 2019-04-25 | 2022-01-14 | 视觉治疗股份有限公司 | 眼用水凝胶酪氨酸激酶抑制剂植入物 |
Non-Patent Citations (4)
Title |
---|
DZHULIYA DZHONOVA ET AL.: "Local release of tacrolimus from hydrogel-based drug delivery system is controlled by inflammatory enzymes in vivo and can be monitored non-invasively using in vivo imaging", 《PLOS ONE.》, vol. 13, no. 8, pages 0203409 * |
LIANGBO CHEN ET AL.: "Injectable bio-responsive hydrogel for therapy of inflammation related eyelid diseases", 《BIOACTIVE MATERIALS》, vol. 6, no. 10, pages 3062 - 3073 * |
MICHAEL L. LOVETT ET AL.: "ilk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》, vol. 95, pages 271 - 278, XP029296800, DOI: 10.1016/j.ejpb.2014.12.029 * |
YAHAN JU ET AL.: "Verteporfin-mediated on/off photoswtching functions synergistically to treat choroidal vascular diseases", BIOACTIVE MATERIALS, no. 14, pages 402 - 415 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115671036A (zh) * | 2022-11-15 | 2023-02-03 | 上海交通大学医学院附属第九人民医院 | 用于治疗眼底和眼内疾病的凝胶药物 |
CN115678048A (zh) * | 2022-11-27 | 2023-02-03 | 福州大学 | 一种可促进创面愈合并减少疤痕形成的可注射复合水凝胶及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114366712B (zh) | 2023-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lynch et al. | Hydrogel biomaterials for application in ocular drug delivery | |
Hashizoe et al. | Scleral plug of biodegradable polymers for controlled drug release in the vitreous | |
EA006746B1 (ru) | Способы лечения глазных неоваскулярных заболеваний | |
Danis et al. | Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide | |
CN114366712B (zh) | 用于治疗脉络膜新生血管的药物凝胶混合物 | |
BRPI0708622A2 (pt) | terapia ocular usando agentes que ativam a sirtuina | |
JP2014510724A (ja) | 熱応答性ハイドロゲル組成物 | |
Chiang et al. | Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection | |
Silva et al. | Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis | |
Hou et al. | Controlled release of dexamethasone from an intravitreal delivery system using porous silicon dioxide | |
Vecino et al. | Glaucoma animal models | |
Rong et al. | Biocompatibility and safety of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel (ICNPH) delivered by subconjunctival injection in rats | |
Das et al. | The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle | |
Ju et al. | Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases | |
Deka et al. | Development, evaluation and characteristics of ophthalmic in situ gel system: a review | |
Jemni-Damer et al. | Biotechnology and biomaterial-based therapeutic strategies for age-related macular degeneration. Part I: Biomaterials-based drug delivery devices | |
JPH05201854A (ja) | 長期放出性眼用製剤 | |
Mittal et al. | Recent advancemnts in biodegradable ocular implants | |
Everaert | Evaluation of newly developed HPMC ophthalmic inserts with sustained release properties as a carrier for thermolabile therapeutics | |
JP2008520546A (ja) | 粘弾性溶液またはゲル製剤およびそれを使って身体部位を処置する方法 | |
Chhetri et al. | In-Situ Forming Polymeric Drug Delivery Systems for Ophthalmic Use: An Overview | |
Bhatt et al. | Modulated approaches for strategic transportation of proteins and peptides via ocular route | |
Garge et al. | Ophthalmic pH sensitive in-situ gel: a review | |
EP1467761B1 (en) | Treatment of neovascular ophthalmic disease | |
RU2405502C1 (ru) | Способ моделирования миопической болезни глаз |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |